A Phase 3 interventional study of Cenvacibart and Placebo in Secondary Stroke, sponsored by Regeneron Pharmaceuticals. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will test an experimental Regeneron drug called cenvacibart (REGN7508) ("study drug") compared with a placebo (a look-alike treatment with no active medicine) on top of background antiplatelet medications.
The purpose of this study is to find out if cenvacibart can safely reduce the risk of another ischemic stroke or another blood clot related events in people who have recently had an ischemic stroke or mini-stroke (TIA).
The study is looking at:
8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.
This study's planned enrollment of 6,106 is above the median of 49 across 6,036 interventional studies indexed under Stroke.
Browse Stroke studies →Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cenvacibart
Drug: Placebo
Administered per the protocol
Also known as: REGN7508
Administered per the protocol
Time to first occurrence of ischemic stroke
Time frame: Approximately 33 months
Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding
Time frame: Approximately 33 months
Total (first and subsequent) ischemic strokes
Time frame: Approximately 33 months
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type)
Time frame: Approximately 33 months
Time to first occurrence of disabling stroke (ischemic, hemorrhagic, or of unspecified type)
Time frame: Approximately 33 months
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type) or TIA
Time frame: Approximately 33 months
Time to first occurrence of TIA
Time frame: Approximately 33 months
Time to all-cause death
Time frame: Approximately 33 months
Time to first occurrence of Major Adverse Cardiovascular Event (MACE) 3 (ischemic stroke, Myocardial Infarction [MI], or cardiovascular [CV] death)
Time frame: Approximately 33 months
Time to first occurrence of ischemic stroke, MI, or all-cause death
Time frame: Approximately 33 months
Time to first occurrence of MACE 4 (ischemic stroke, MI, CV death, or arterial revascularization procedure), systemic embolism, MALE (acute limb ischemia or major amputation [above the ankle] of vascular etiology), or venous thromboembolism (VTE)
Time frame: Approximately 33 months
Time to first occurrence of VTE
Time frame: Approximately 33 months
Time to first occurrence of ischemic stroke or ISTH major bleeding
Time frame: Approximately 33 months
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), MI, ISTH major bleeding, or CV death
Time frame: Approximately 33 months
Time to first occurrence of disabling stroke (ischemic, hemorrhagic, or of unspecified type), symptomatic intracranial hemorrhage, or all-cause death
Time frame: Approximately 33 months
Time to first occurrence of ISTH major or ISTH clinically relevant non-major bleeding
Time frame: Approximately 33 months
Total ISTH major or ISTH clinically relevant non-major bleeding events
Time frame: Approximately 33 months
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Time frame: Approximately 36 months
Severity of TEAEs
Time frame: Approximately 36 months
Occurrence of Anti-Drug Antibodies (ADAs) to cenvacibart
Time frame: Approximately 33 months
Magnitude of ADAs to cenvacibart
Time frame: Approximately 33 months
Concentrations of cenvacibart
Time frame: Approximately 33 months
Change in activated Partial Thromboplastin Time (aPTT)
Time frame: Approximately 33 months
Change in Prothrombin Time (PT)
Time frame: Approximately 33 months
No study locations are listed for this record.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Dec 2029, 36 months later.
Of 37 industry-sponsored phase 3 interventional studies under Stroke, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 58. This study's planned 36 months is close to that.
Counting every sponsor, half of 129 studies reached it within 44 months; a quarter within 27 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cenvacibart